FPR2 and early-onset autosomal dominant Alzheimer disease: Interestingly, in our previous study, we observed that the beneficial impact of the structurally related FPR2 agonist MR-39 was also limited to the suppression of microgliosis but not astrogliosis in an in vivo model of Alzheimer’s disease [48].